UBS initiated coverage of CG Oncology (CGON) with a Buy rating and $60 price target The firm launched coverage of SMID cap biotech sector with a focus in oncology and autoimmune diseases. Its top pick is Syndax. CG Oncology has a highly differentiated bladder cancer therapy and UBS expects significant market adoption upon approval, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CGON:
- J&J trial miss may be viewed positively for CG Oncology, says BofA
- enGene price target lowered to $17 from $26 at Leerink
- CG Oncology initiated with an Outperform at RBC Capital
- J&J data presents ‘limited downside’ to CG Oncology, says Goldman Sachs
- CG Oncology initiated with a Buy at Roth MKM
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
